On 21 June 2011, orphan designation (EU/3/11/874) was granted by the European Commission to TMC Pharma Services Ltd, United Kingdom, for human embryonic stem-cell-derived retinal pigment epithelial cells for the treatment of Stargardt's disease.
The sponsorship was transferred to Astellas Pharma Europe B.V, The Netherlands, in December 2016.
Human embryonic stem-cell-derived retinal pigment epithelial cells
|Disease / condition||
Treatment of Stargardt's disease
|Date of first decision||
|EU designation number||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.